A Look at 10x Genomics Inc (TXG) After 3.5% Decline -- GF Value $18.31 vs Price $69.86
On October 16, 2026, 10x Genomics Inc (TXG) shares fell 3.5%, bringing the current price to $69.86. The stock has experienced significant price fluctuations, wi
TXG - 10x Genomics, Inc.
Price:
--
--
|
CONSENSUS:
Hold
DETAILS
|
PRICE TARGET:
$83.30
DETAILS
HIGH:
$110.00
LOW:
$65.00
MEDIAN:
$75.00
CONSENSUS:
$83.30
UPSIDE:
19.24%
Stock News
10x Genomics to Report Third Quarter 2026 Financial Results on November 5, 2026
PLEASANTON, Calif., Oct. 13, 2026 /PRNewswire/ -- 10x Genomics, Inc. (Nasdaq: TXG), the life science technology leader focused on accelerating science and advancing human health, announced it will report financial results for the third quarter ended September 30, 2026 after market close on Thursday, November 5, 2026.
These 3 Stocks Are Crushing the "Magnificent Seven" This Year -- Are They Still Buys?
Forget the "Magnificent Seven" in favor of the "Tremendous Three"?
10x Genomics & Fred Hutch Join Forces on Cancer Biomarker Research
TXG teams up with Fred Hutchinson Cancer Center to advance precision oncology through single-cell and spatial technologies targeting two cancer types.
10x Genomics Announces New Collaboration to Advance Single Cell and Spatial Applications Across Solid Tumors and Blood Cancers
Multi-project collaboration with Fred Hutch Cancer Center spans biomarker discovery in bladder cancer and a single cell approach to residual disease detection in acute myeloid leukemia PLEASANTON, Calif., Oct. 7, 2026 /PRNewswire/ -- 10x Genomics, Inc. (Nasdaq: TXG), the life science technology leader focused on accelerating science and advancing human health, today announced a multi-project research collaboration with Fred Hutchinson Cancer Center (Fred Hutch), one of the nation's leading cancer research institutions, to advance the use of single cell and spatial technologies in both solid tumor and hematologic malignancies.
Torex Gold Targets Growth, C$350M Returns and Morelos Expansion
Torex Gold Resources (TSE: TXG) outlined plans to build on production from its Morelos property in Mexico, advance the Los Reyes development project and return capital to shareholders as it seeks to close what it described as a valuation gap. During a company presentation, Andrew, a Torex speaker, said the company's strategy rests on "strong execution,
10x Genomics Begins Atera Shipments as Spatial Biology Demand Rises
TXG begins Atera shipments as orders top 40 systems, highlighting strong early demand and broad research interest in its spatial biology platform.
10x Genomics Announces Sentira, a New Computational Platform to Turn Complex Biological Data Into Experimental Conclusions
Sentira Spatial Analysis leverages NVIDIA accelerated computing to cut spatial data processing times from hours to minutes, putting rapid, iterative analysis at the fingertips of every researcher PLEASANTON, Calif., Sept. 29, 2026 /PRNewswire/ -- 10x Genomics, Inc. (Nasdaq: TXG), the life science technology leader focused on accelerating science and advancing human health, today announced Sentira, a new cloud analysis platform that extends the 10x experience from data generation to experimental conclusions, beginning with Sentira Spatial Analysis.
10x Genomics Begins Global Shipments of Atera, Putting Unprecedented Spatial Biology Capabilities in Researchers' Hands
Extraordinary early global demand, ambitious new research programs and an expansive technology roadmap mark the beginning of a new era for biological understanding PLEASANTON, Calif., Sept. 29, 2026 /PRNewswire/ -- 10x Genomics, Inc. (Nasdaq: TXG), the life science technology leader focused on accelerating science and advancing human health, today announced the first commercial shipments of Atera, marking a major milestone for a platform that will redefine what's possible in spatial biology.
10x Genomics (NASDAQ:TXG) Stock: Insider Shehnaaz Suliman Sells 5,723 Shares
10x Genomics (NASDAQ: TXG - Get Free Report) Director Shehnaaz Suliman sold 5,723 shares of the business's stock in a transaction on Tuesday, September 22nd. The stock was sold at an average price of $81.19, for a total transaction of $464,650.37. Following the transaction, the director directly owned 23,792 shares of the company's stock, valued at
10x Genomics (NASDAQ:TXG) Stock: Insider Serge Saxonov Sells 25,000 Shares
10x Genomics (NASDAQ: TXG - Get Free Report) CEO Serge Saxonov sold 25,000 shares of 10x Genomics stock in a transaction that occurred on Tuesday, September 22nd. The stock was sold at an average price of $81.22, for a total value of $2,030,500.00. Following the completion of the transaction, the chief executive officer directly owned 1,050,249
3 Analysts, 3 Trades to Make Today
Louis says buy the AI dip
10x Genomics Inc (TXG) Shares Surge 3.3% -- What GF Score of 56 Tells Investors
On September 21, 2026, 10x Genomics Inc (TXG) shares rose 3.3% to a current price of $79.10. The stock has seen a remarkable performance over the past year, wit
Analyzing MindWalk (NASDAQ:HYFT) & 10x Genomics (NASDAQ:TXG)
10x Genomics (NASDAQ: TXG - Get Free Report) and MindWalk (NASDAQ: HYFT - Get Free Report) are both healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their valuation, profitability, institutional ownership, risk, earnings, dividends and analyst recommendations. Profitability This table compares 10x Genomics and MindWalk's net
HB Wealth Management LLC Invests $285,000 in 10x Genomics $TXG
HB Wealth Management LLC purchased a new stake in 10x Genomics (NASDAQ: TXG) in the undefined quarter, according to its most recent Form 13F filing with the SEC. The firm purchased 7,444 shares of the company's stock, valued at approximately $285,000. Other institutional investors have also recently modified their holdings of the company.
Lunit Announces Collaboration with 10x Genomics to Integrate AI-Enabled Pathology Analysis with Spatial Molecular Data for Oncology Clinical Research
10x Genomics, a leader in single-cell and spatial biology, to combine its spatial biology technologies with Lunit's AI-powered H&E pathology analysis to advance oncology biomarker discovery SEOUL, South Korea, Sept. 10, 2026 /PRNewswire/ -- Lunit (KRX: 328130), a leading provider of AI for cancer diagnostics and precision oncology, today announced that 10x Genomics, Inc. (Nasdaq: TXG) will incorporate Lunit's AI-powered pathology platform, Lunit SCOPE IO, into its oncology biomarker discovery workflow.
10x Genomics Inc (TXG) Stock Up 4.7% but GF Value Says Overvalued -- GF Score: 56/100
On September 08, 2026, 10x Genomics Inc (TXG) shares rose 4.7% today, bringing the current price to $65.61. The stock has seen significant volatility over the p
10x Genomics Rallies 84% in 3 Months: Is There More Upside Ahead?
TXG's 84% rally is backed by consumables growth, Atera demand and higher guidance, but weak instruments and valuation raise the bar.
Next Biotech Boom May Be Cancer Vaccines: Watch These ETFs
The biotech sector has a new catalyst beyond GLP-1 drugs. Moderna Inc (NASDAQ:MRNA) and Merck & Co Inc's (NYSE:MRK) positive Phase 3 results for a personalized mRNA cancer vaccine could revive investor interest in genomics, immunotherapy and precision medicine ETFs.
TXG Stock Down Despite Patent Verdict Win Against Parse Biosciences
10x Genomics wins a $4.8M patent verdict against Parse, strengthening its IP position as it seeks added damages and a U.S. injunction.
Price Targets
10X Genomics (TXG) PT Raised to $70 at TD Cowen
$70.00
(was $72.68)
Stifel Nicolaus
10x Genomics price target raised to $70 from $40 at Morgan Stanley
$70.00
(was $78.95)
Morgan Stanley
10x Genomics price target raised to $100 from $60 at Canaccord
$100.00
(was $80.65)
Kyle Mikson
·
Canaccord Genuity
10x Genomics price target raised to $110 from $52 at Barclays
$110.00
(was $80.66)
Barclays
10x Genomics price target raised to $90 from $40 at Leerink
$90.00
(was $88.42)
Leerink Partners
10x Genomics initiated with a Buy at Argus
$110.00
(was $85.71)
Argus Research
10x Genomics price target raised to $80 from $47 at Piper Sandler
$80.00
(was $85.71)
Piper Sandler
10x Genomics assumed with a Neutral at UBS
$68.00
(was $65.60)
Doug Schenkel
·
UBS
RBC Capital Starts 10X Genomics (TXG) at Sector Perform
$70.00
(was $62.45)
Dan Leonard
·
RBC Capital
10x Genomics price target raised to $65 from $50 at Stephens
$65.00
(was $58.34)
Mason Carrico
·
Stephens
10x Genomics price target raised to $47 from $42 at Piper Sandler
$47.00
(was $52.03)
Piper Sandler
10X Genomics (TXG) PT Raised to $60 at Canaccord
$60.00
(was $52.03)
Kyle Mikson
·
Canaccord Genuity
10x Genomics price target raised to $40 from $37 at Morgan Stanley
$40.00
(was $48.31)
Morgan Stanley
10x Genomics price target raised to $50 from $25 at Stifel
$50.00
(was $47.15)
Stifel Nicolaus
10x Genomics price target raised to $40 from $23 at Leerink
$40.00
(was $44.12)
Leerink Partners
10x Genomics price target raised to $50 from $32 at Canaccord
$50.00
(was $41.77)
Kyle Mikson
·
Canaccord Genuity
10x Genomics price target raised to $37 from $22 at Morgan Stanley
$37.00
(was $37.47)
Kallum Titchmarsh
·
Morgan Stanley
10x Genomics price target raised to $40 from $30 at Barclays
$40.00
(was $31.87)
Luke Sergott
·
Barclays
10x Genomics price target raised to $22 from $20 at Morgan Stanley
$22.00
(was $20.60)
Morgan Stanley
10x Genomics price target raised to $30 from $22 at Barclays
$30.00
(was $23.58)
Barclays